Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug.

X
Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Raltegravir (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms BENCHMRK-2
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 12 May 2022 A systematic literature review was conducted to identify trials with designs and populations comparable to BRIGHTE, results published in the Clinical Therapeutics
    • 27 Jul 2012 5-Year results from a pooled analysis of BENCHMRK I and II presented at the 19th International AIDS Conference.
    • 22 Jul 2012 Five-year results have been presented at the 19th International AIDS Conference according to a Merck media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top